TY - JOUR
T1 - American society of clinical oncology statement
T2 - Biosimilars in oncology
AU - Lyman, Gary H.
AU - Balaban, Edward
AU - Diaz, Michael
AU - Ferris, Andrea
AU - Tsao, Anne
AU - Voest, Emile
AU - Zon, Robin
AU - Francisco, Michael
AU - Green, Sybil
AU - Sherwood, Shimere
AU - Harvey, R. Donald
AU - Schilsky, Richard L.
N1 - Publisher Copyright:
© 2018 by American Society of Clinical Oncology.
PY - 2018/4/20
Y1 - 2018/4/20
N2 - As many biosimilars come to market in the next several years, their use in oncology will play an important role in the future care of patients with cancer. ASCO is committed to providing education and guidance to the oncology community on the use of biosimilars in the cancer setting; therefore, ASCO has developed this statement to offer guidance in the following areas: (1) naming, labeling, and other regulatory considerations, (2) safety and efficacy of biosimilars, (3) interchangeability, switching, and substitution, (4) value of biosimilars, and (5) prescriber and patient education.
AB - As many biosimilars come to market in the next several years, their use in oncology will play an important role in the future care of patients with cancer. ASCO is committed to providing education and guidance to the oncology community on the use of biosimilars in the cancer setting; therefore, ASCO has developed this statement to offer guidance in the following areas: (1) naming, labeling, and other regulatory considerations, (2) safety and efficacy of biosimilars, (3) interchangeability, switching, and substitution, (4) value of biosimilars, and (5) prescriber and patient education.
UR - http://www.scopus.com/inward/record.url?scp=85045639116&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045639116&partnerID=8YFLogxK
U2 - 10.1200/JCO.2017.77.4893
DO - 10.1200/JCO.2017.77.4893
M3 - Article
C2 - 29443651
AN - SCOPUS:85045639116
SN - 0732-183X
VL - 36
SP - 1260
EP - 1265
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 12
ER -